ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.